Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
1
33%
Ph early_phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedearly_phase_1

Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis

NCT04445025
completedphase_2

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

NCT04051320
completedphase_3

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

NCT04914195

Clinical Trials (3)

Showing 3 of 3 trials
NCT04445025Early Phase 1

Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis

Completed
NCT04051320Phase 2

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

Completed
NCT04914195Phase 3

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3